Home Cart Sign in  
Chemical Structure| 267243-28-7 Chemical Structure| 267243-28-7

Structure of Canertinib
CAS No.: 267243-28-7

Chemical Structure| 267243-28-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.

Synonyms: CI-1033; PD-183805

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Canertinib

CAS No. :267243-28-7
Formula : C24H25ClFN5O3
M.W : 485.94
SMILES Code : C=CC(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN4CCOCC4)=O
Synonyms :
CI-1033; PD-183805
MDL No. :MFCD09837878

Safety of Canertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Canertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:1.5 nM

  • HER2/ErbB2

    ErbB2, IC50:9.0 nM

  • HER2

    ErbB2, IC50:9.0 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00174356 Carcinoma, Non-Small Cell Lung Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Illinois Pfizer Investigational Site Park Ridge, Illinois, United States, 60068 Pfizer Investigational Site Skokie, Illinois, United States, 60076 United States, Kentucky Pfizer Investigational Site Louisville, Kentucky, United States, 40202 Pfizer Investigational Site Louisville, Kentucky, United States, 40207 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77030 Canada, Ontario Pfizer Investigational Site Hamilton, Ontario, Canada, L8V 5C2 Less <<
NCT00050830 Lung Neoplasms Phase 2 Completed - -
NCT00051051 Breast Neoplasms Phase 2 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories